Fanzhuoran Lou

Xiamen, 361004, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Phase III Trial: Single Low-Dose 5 mg Dexamethasone with NEPA for Preventing 168 h Nausea and Vomiting of Diverse Highly or Moderately Emetogenic Chemotherapy (LD-NEPA).

Phase III Trial: Single Low-Dose 5 mg Dexamethasone with NEPA for Preventing 168 h Nausea and Vomiting of Diverse Highly or Moderately Emetogenic Chemotherapy (LD-NEPA).

Journal: Diseases (Basel, Switzerland)
Published: May 08, 2026

Lentiviral Dendritic Cell Vaccine Targeting Claudin-18.2 Elicits Potent Antitumor Immunity Against Gastric Cancer.

Lentiviral Dendritic Cell Vaccine Targeting Claudin-18.2 Elicits Potent Antitumor Immunity Against Gastric Cancer.

Journal: Cancers
Published: December 05, 2025

Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer.

Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer.

Journal: NPJ precision oncology
Published: November 17, 2025

Claudin18.2 promote gastric cancer proliferation by activating MCM2/5.

Claudin18.2 promote gastric cancer proliferation by activating MCM2/5.

Journal: Scientific reports
Published: September 24, 2025

CDK4/6i reverse PARPi resistance by targeting the E2F1- MCM2/5 pathway.

CDK4/6i reverse PARPi resistance by targeting the E2F1- MCM2/5 pathway.

Journal: NPJ precision oncology
Published: August 25, 2025

Efficacy of single low-dose dexamethasone with NEPA for the 168 h prevention of highly or moderately emetogenic chemotherapy.

Efficacy of single low-dose dexamethasone with NEPA for the 168 h prevention of highly or moderately emetogenic chemotherapy.

Journal: Frontiers in pharmacology
Published: May 04, 2025

Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).

Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).

Journal: Cancers
Published: January 10, 2025

Exo70 Promotes the Invasion of Pancreatic Cancer Cells via the Regulation of Exosomes.

Exo70 Promotes the Invasion of Pancreatic Cancer Cells via the Regulation of Exosomes.

Journal: Cancers
Published: December 04, 2023
Showing 1-8 of 8

Last Updated: 09/26/2026